{"id":76474,"date":"2022-07-28T14:06:37","date_gmt":"2022-07-28T14:06:37","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=95707"},"modified":"2022-07-28T14:06:37","modified_gmt":"2022-07-28T14:06:37","slug":"sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/","title":{"rendered":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study"},"content":{"rendered":"
\n

DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084<\/a> long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through November 5, 2021).<\/p>\n

\u201cThese results are encouraging as CAB efficacy was sustained during the 12 months following unblinding, confirming a high level of protection against HIV acquisition among study participants assigned female at birth,\u201d said Dr. Sinead Delany-Moretlwe, HPTN 084 protocol chair, director of research at Wits RHI, and research professor at the University of the Witwatersrand in Johannesburg, South Africa.<\/p>\n

HPTN 084 is an ongoing Phase 3 randomized, controlled trial that previously demonstrated the superiority of ViiV Healthcare\u2019s long-acting cabotegravir compared to daily oral tenofovir\/emtricitabine (TDF\/FTC) for HIV prevention in individuals assigned female at birth. The blinded portion of the trial was stopped at a planned interim review in November 2020 due to evidence of superior efficacy when compared to daily oral TDF\/FTC. Participants were subsequently unblinded and continued their original randomized study regimen pending a protocol amendment to offer open-label CAB.<\/p>\n

\u201cHIV infection continues to threaten the health of women worldwide,\u201d said Dr. Myron Cohen, HPTN co-principal investigator, and director of the Institute for Global Health at the University of North Carolina in Chapel Hill. \u201cEmpowering women with safe and effective PrEP options is critical to reducing HIV as a global health threat.\u201d<\/p>\n

HPTN 084 enrolled 3,223 cisgender women at research sites in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Twenty-three incident infections (3 CAB, 20 TDF\/FTC) were detected in the 12-month unblinded period. Of these, two (1 CAB, 1 TDF\/FTC) were determined to have occurred during the blinded phase. Only one of the CAB cases (blinded phase case) had ever received an injection. An additional 83 confirmed pregnancies (43 CAB, 40 TDF\/FTC) occurred in the unblinded period. No congenital anomalies were reported.<\/p>\n

\u201cThe additional pregnancy incidence data highlight the importance of establishing the safety and pharmacology of CAB among pregnant individuals,\u201d said Dr. Wafaa El-Sadr, HPTN co-principal investigator, director of ICAP, and professor of epidemiology and medicine at Columbia University in New York.<\/p>\n

HPTN 084 was co-funded by NIAID, the Bill & Melinda Gates Foundation, and ViiV Healthcare. Study product was provided by ViiV Healthcare and Gilead Sciences, Inc. Three other NIH institutes also collaborated on HPTN 084: the National Institute of Mental Health, the National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.<\/p>\n

About HPTN<\/u><\/b><\/p>\n

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health, Office of The Director,\u202fthe U.S. National Institute on Drug Abuse, and the\u202fEunice Kennedy Shriver National Institute of Child Health and Human Development,\u202fall part of the U.S. National Institutes of Health,\u202fco-fund the HPTN. The HPTN has collaborated with more than 85 clinical research sites in 19 countries to evaluate new HIV prevention interventions and strategies in populations with a disproportionate HIV burden. The HPTN research agenda \u2013 more than 50 trials ongoing or completed with over 161,000 participants enrolled and evaluated \u2013 is focused primarily on discovering new HIV prevention tools and evaluating integrated strategies, including biomedical interventions combined with behavioral risk reduction interventions and structural interventions. For more information, visit\u202fhptn.org<\/a>.<\/p>\n


\n<\/p>\n

Eric Miller\r\nHIV Prevention Trials Network (HPTN)\r\n9193846465\r\nemiller@fhi360.org<\/a>\r\n<\/pre>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) \u2014 Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,182,17,53,343,32],"tags":[],"yoast_head":"\nSustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette\" \/>\n<meta property=\"og:description\" content=\"DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) \u2014 Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Lebanon News Gazette\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T14:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=\" \/>\n<meta name=\"author\" content=\"lnadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"lnadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\"},\"author\":{\"name\":\"lnadmin\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\"},\"headline\":\"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study\",\"datePublished\":\"2022-07-28T14:06:37+00:00\",\"dateModified\":\"2022-07-28T14:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\"},\"wordCount\":606,\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=\",\"articleSection\":[\"Africa\",\"Asean\",\"MENA\",\"Pakistan\",\"Press Releases\",\"South Africa\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\",\"name\":\"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette\",\"isPartOf\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=\",\"datePublished\":\"2022-07-28T14:06:37+00:00\",\"dateModified\":\"2022-07-28T14:06:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage\",\"url\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=\",\"contentUrl\":\"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lebanonnewsgazette.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#website\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"name\":\"Lebanon News Gazette\",\"description\":\"News from Lebanon\",\"publisher\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#organization\",\"name\":\"Lebanon News Gazette\",\"url\":\"https:\/\/lebanonnewsgazette.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"contentUrl\":\"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png\",\"width\":503,\"height\":261,\"caption\":\"Lebanon News Gazette\"},\"image\":{\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840\",\"name\":\"lnadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"lnadmin\"},\"url\":\"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/","og_locale":"en_US","og_type":"article","og_title":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette","og_description":"DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) \u2014 Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November [\u2026]","og_url":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/","og_site_name":"Lebanon News Gazette","article_published_time":"2022-07-28T14:06:37+00:00","og_image":[{"url":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY="}],"author":"lnadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"lnadmin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#article","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/"},"author":{"name":"lnadmin","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840"},"headline":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study","datePublished":"2022-07-28T14:06:37+00:00","dateModified":"2022-07-28T14:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/"},"wordCount":606,"publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage"},"thumbnailUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=","articleSection":["Africa","Asean","MENA","Pakistan","Press Releases","South Africa"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/","url":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/","name":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Lebanon News Gazette","isPartOf":{"@id":"https:\/\/lebanonnewsgazette.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage"},"thumbnailUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=","datePublished":"2022-07-28T14:06:37+00:00","dateModified":"2022-07-28T14:06:37+00:00","breadcrumb":{"@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#primaryimage","url":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=","contentUrl":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/lebanonnewsgazette.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lebanonnewsgazette.com\/"},{"@type":"ListItem","position":2,"name":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study"}]},{"@type":"WebSite","@id":"https:\/\/lebanonnewsgazette.com\/#website","url":"https:\/\/lebanonnewsgazette.com\/","name":"Lebanon News Gazette","description":"News from Lebanon","publisher":{"@id":"https:\/\/lebanonnewsgazette.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lebanonnewsgazette.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lebanonnewsgazette.com\/#organization","name":"Lebanon News Gazette","url":"https:\/\/lebanonnewsgazette.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/","url":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","contentUrl":"https:\/\/lebanonnewsgazette.com\/wp-content\/uploads\/2020\/07\/cropped-lebanonnewsgazette-logo-1.png","width":503,"height":261,"caption":"Lebanon News Gazette"},"image":{"@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/b220111f97227f75d2130729cf3e0840","name":"lnadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lebanonnewsgazette.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"lnadmin"},"url":"https:\/\/lebanonnewsgazette.com\/author\/lnadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/76474"}],"collection":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/comments?post=76474"}],"version-history":[{"count":0,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/posts\/76474\/revisions"}],"wp:attachment":[{"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/media?parent=76474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/categories?post=76474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lebanonnewsgazette.com\/wp-json\/wp\/v2\/tags?post=76474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}